The First RAS Inhibitor to Beat Pancreatic Cancer: What Daraxonrasib’s Phase 3 Survival Data Means for Oncology

A Phase 3 trial reported a 60 percent reduction in the risk of death for patients with metastatic pancreatic ductal adenocarcinoma. After sixty years of near-total treatment stagnation in one of medicine’s hardest cancers, the data behind daraxonrasib may be the most consequential oncology result of 2026.

Presented By Our Partners

On April 13, 2026, Revolution Medicines announced that its investigational drug daraxonrasib had met both primary endpoints in the global Phase 3 RASolute 302 clinical trial, reporting a median overall survival of 13.2 months in patients with previously treated metastatic pancreatic ductal adenocarcinoma, compared to 6.7 months for standard-of-care chemotherapy. The hazard ratio was 0.40 with a p-value below 0.0001, meaning a 60 percent reduction in the risk of death. In a disease where the five-year survival rate for metastatic patients is below five percent, those numbers represent something genuinely unprecedented.

To understand why this matters, you first need to understand why pancreatic cancer has been so resistant to the advances that reshaped survival rates in other cancers over the past three decades.

Why Pancreatic Cancer Became Medicine’s Hardest Problem

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, has a five-year survival rate of roughly nine to ten percent across all stages. For patients diagnosed with metastatic disease, which accounts for the majority of cases at diagnosis because early pancreatic cancer rarely produces symptoms, that number collapses to below five percent. The median overall survival for patients receiving modern combination chemotherapy regimens such as modified FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) or gemcitabine plus nab-paclitaxel has hovered between eight and twelve months, with no meaningful improvement in decades.

The reasons for this stagnation are structural. Pancreatic tumors develop a dense, fibrous stroma, a kind of biological fortress that prevents immune cells and many drugs from penetrating effectively. The disease is detected late, almost universally, because the pancreas sits deep in the abdomen and its early dysfunction produces vague, easily attributed symptoms. And most critically, approximately 90 percent of pancreatic cancers are driven by mutations in the RAS gene, a molecular switch that was identified as oncogenic in the 1980s but was considered essentially undruggable for nearly forty years.

RAS proteins function as critical signal relays inside cells. In their normal state, they cycle between an active (GTP-bound) and inactive (GDP-bound) form, turning growth signals on and off. A KRAS mutation, the most common form in pancreatic cancer, locks the protein in its active, growth-promoting state. Cells with mutant KRAS receive a constant signal to divide, regardless of what the body needs. Among KRAS mutations in pancreatic ductal adenocarcinoma, approximately 40 percent are G12D, 29 percent are G12V, and 15 percent are G12R. These three variants collectively represent the oncogenic foundation of most pancreatic cancers.

The challenge that stalled drug development for four decades was pharmacological. The RAS protein has a smooth surface with no obvious binding pocket where a small molecule could attach. The GTP molecule that activates it binds with extremely high affinity, making competitive inhibition impractical. Early RAS inhibitors that targeted downstream effectors like MEK showed limited durability because tumors rapidly found alternative signaling routes. A separate class of allele-specific inhibitors, most notably sotorasib and adagrasib targeting KRAS G12C, achieved meaningful results in lung cancer, but the G12C variant accounts for fewer than two percent of pancreatic cancers. The vast majority of PDAC patients had no targeted option whatsoever.

The Molecular Breakthrough: RAS(ON) Inhibition and the Tri-Complex Mechanism

Daraxonrasib, developed by Revolution Medicines under its earlier designation as RMC-6236, takes a fundamentally different approach. Rather than targeting the inactive form of RAS, or attempting to block GTP binding directly, daraxonrasib is a RAS(ON) multi-selective inhibitor that targets the active, GTP-bound state of RAS proteins, including both mutant and wild-type forms.

The mechanism relies on what researchers describe as a molecular glue approach. Daraxonrasib first binds to cyclophilin A, a chaperone protein naturally present inside cells, forming a bicomplex. This bicomplex then binds to the active form of RAS, creating a tri-complex structure. The formation of this tri-complex disrupts the interaction between RAS and its downstream effector proteins, blocking the signals that drive tumor growth. For tumors carrying codon 12 mutations, the tri-complex forms in a relatively unstable configuration that also accelerates GTP hydrolysis, effectively increasing the rate at which the oncogenic RAS is inactivated.

Critically, because daraxonrasib targets the active state rather than a specific mutant amino acid, it can suppress signaling across multiple RAS variants simultaneously. This broad coverage addresses G12D, G12V, G12R, and other codon 12 and codon 13 variants, as well as Q61 mutations. In pancreatic cancer, where the mutational landscape is heterogeneous even within the G12 class, this multi-selectivity is not a pharmacological nicety but a clinical requirement. A drug locked to a single allele would be irrelevant to the majority of PDAC patients.

This approach also addresses a known resistance mechanism. Allele-specific inhibitors that lock onto a single mutant form are vulnerable to secondary mutations at adjacent positions that restore RAS activity while evading the drug. A broad-spectrum RAS(ON) inhibitor that targets the structural conformation of active RAS, rather than one specific amino acid, creates a significantly higher barrier to this form of acquired resistance.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The RASolute 302 Trial: What Was Tested and Who Was Enrolled

The RASolute 302 study was a global, randomized, controlled Phase 3 registrational trial enrolling approximately 501 adult patients with histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma who had received at least one prior line of therapy. Patients were randomized to receive daraxonrasib at 300 mg orally once daily or investigator’s choice of standard-of-care cytotoxic chemotherapy administered intravenously.

The trial enrolled a broad population reflecting the real-world mutational landscape of PDAC. This included patients with tumors harboring G12D, G12V, and G12R mutations, as well as patients with RAS wild-type tumors. The primary endpoints were progression-free survival and overall survival in patients with RAS G12 mutation-positive tumors, assessed by blinded independent central review.

The oral once-daily dosing of daraxonrasib stands in sharp contrast to the intravenous chemotherapy regimens it was compared against. FOLFIRINOX requires a multi-hour infusion every two weeks, with a side effect burden that includes significant nausea, neuropathy, hair loss, and immunosuppression. Gemcitabine-based regimens carry similar systemic toxicities. Daraxonrasib’s safety profile across the trial was described as generally well tolerated, with no new safety signals identified. For a patient population that is often debilitated by both disease and prior treatment, the difference between an oral pill and an infusion chair is not trivial.

Reading the Numbers: Why a Hazard Ratio of 0.40 Is Extraordinary

The headline figures from RASolute 302 are striking by any oncology standard. A median overall survival of 13.2 months versus 6.7 months on chemotherapy represents not a modest improvement but a near-doubling of survival time. The hazard ratio of 0.40 means that at any given point during the trial, patients on daraxonrasib had 40 percent of the risk of dying compared to patients on chemotherapy. Stated differently, the drug reduced the risk of death by 60 percent.

To put that in context: the approval of nab-paclitaxel plus gemcitabine over gemcitabine alone in 2013, which represented a major advance at the time, was based on a hazard ratio of 0.72, a 28 percent reduction in the risk of death. The approval of modified FOLFIRINOX over gemcitabine showed a hazard ratio of approximately 0.57. Daraxonrasib’s hazard ratio of 0.40, in a previously treated population no less, substantially outperforms both of the regimens that currently define standard of care.

The previously treated setting matters here. Patients enrolled in RASolute 302 had already received at least one chemotherapy regimen and had progressed. Their tumors were, by definition, more resistant than treatment-naive disease. Achieving a 60 percent reduction in death risk in this population is an exceptional pharmacological result that would typically predict strong performance in a first-line setting as well.

Revolution Medicines has already initiated planning for RASolute 303, a global Phase 3 registrational trial of daraxonrasib in first-line metastatic PDAC. Earlier Phase 1 and Phase 2 data presented at the 2026 American Association for Cancer Research Annual Meeting showed that daraxonrasib demonstrated meaningful antitumor activity both as monotherapy and in combination with chemotherapy in treatment-naive patients, setting the stage for what could be an even larger efficacy signal in patients who have not yet been exposed to prior treatment.

Regulatory Pathway and What Comes Next

The FDA granted daraxonrasib Breakthrough Therapy Designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations, a designation that provides more intensive FDA guidance and can streamline the review process. The agency has also permitted an expanded access protocol, allowing eligible patients who fall outside clinical trial criteria to access the drug while regulatory review proceeds.

Revolution Medicines has announced plans to present the full RASolute 302 dataset at the 2026 American Society of Clinical Oncology Annual Meeting in a plenary session, one of the highest-profile stages in oncology. Following that presentation, the company intends to file a New Drug Application with the FDA under a Commissioner’s National Priority Voucher, a designation reserved for therapies addressing unmet medical needs of national importance. Submissions to regulatory authorities in other countries will follow.

If approved, daraxonrasib would represent the first targeted therapy approved specifically for the majority of pancreatic cancer patients based on RAS mutation status. Given the drug’s multi-selective mechanism, it may also have relevance in other RAS-driven cancers. KRAS mutations are prevalent in colorectal cancer (approximately 40 percent of cases), non-small cell lung cancer (roughly 30 percent), and a range of other solid tumors. Researchers at Revolution Medicines and partner institutions are already evaluating daraxonrasib in these contexts, and the breadth of the RAS(ON) inhibition approach could, in principle, make this drug class relevant across a substantial fraction of all solid tumor oncology.

The Precision Oncology Context: From Target Identification to Clinical Proof

The arc of the RAS story is one of the most important in modern oncology. RAS was among the first human oncogenes ever identified. A landmark 1982 paper from Robert Weinberg’s laboratory at MIT demonstrated that mutant RAS could transform normal cells into cancer cells. In the years that followed, the oncology research community poured enormous resources into developing RAS inhibitors, and failed repeatedly. By the 1990s, the RAS protein had acquired the label “undruggable,” a term that became something close to scientific consensus and remained so for nearly three decades.

The first crack in that consensus came in 2019, when Amgen researchers published structural work showing that the KRAS G12C mutant had a previously unappreciated binding pocket that appeared only in the inactive state. That insight led to the development of sotorasib and adagrasib, the first allele-specific RAS inhibitors to reach clinical approval, which were approved for KRAS G12C-mutant non-small cell lung cancer in 2021 and 2022 respectively. But G12C is uncommon in pancreatic cancer, leaving the vast majority of PDAC patients without a targeted option.

Revolution Medicines took the next conceptual leap: rather than targeting one allele in one state, target the active conformation broadly. The RAS(ON) platform was built on structural biology, computational chemistry, and a detailed understanding of cyclophilin A biology, ultimately producing a drug that overcomes the resistance that stalled the entire field for sixty years. The Phase 3 data from RASolute 302 is the clinical validation of that approach.

It is also a meaningful data point for the broader precision oncology thesis: that cancers defined by specific molecular drivers can be matched to drugs designed against those drivers, producing survival benefits that generic chemotherapy cannot approach. The genomic profiling technology that identifies KRAS G12 mutations in tumor tissue is now widely available, often through liquid biopsy as well as traditional tumor biopsy. In a world where daraxonrasib is approved, mutation testing at diagnosis becomes a first-order clinical priority for every pancreatic cancer patient.

What This Means For You

If you or someone you love has been diagnosed with pancreatic cancer, or if you are managing the care of a patient with this disease, the daraxonrasib data from RASolute 302 is genuinely the most significant development in this field in decades. While the drug is not yet FDA-approved, expanded access protocols are already in place for eligible patients who have progressed on prior therapy and whose tumors harbor KRAS G12 mutations. Oncologists with experience in pancreatic cancer and access to centers participating in Revolution Medicines’ expanded access program may be able to evaluate whether a patient qualifies.

If you are not currently dealing with pancreatic cancer, the implications are still worth understanding. First, this trial establishes that RAS, once declared undruggable, is now a validated therapeutic target with a drug that delivers Phase 3 overall survival benefit. That changes the calculus for other RAS-driven cancers including colorectal and lung cancers, where daraxonrasib trials are either underway or in active planning. Second, the success of the RAS(ON) approach validates a strategy of targeting protein conformation rather than a specific mutation, a concept that could unlock other long-intractable oncology targets.

From a personal health intelligence standpoint, the rise of multi-cancer early detection tests and liquid biopsy platforms makes this development particularly relevant. Tests that can detect pancreatic cancer at earlier stages, combined with drugs that now demonstrate meaningful efficacy even in advanced, previously treated disease, create a dramatically improved landscape for a cancer that was, until very recently, diagnosed too late and treated too ineffectively at every stage. The foundational pillars of nutrition, movement, and metabolic health remain the best tools for primary prevention of cancer across the board. But for those who face a pancreatic cancer diagnosis despite those precautions, the science has just moved decisively in the right direction.

The full RASolute 302 dataset will be presented at ASCO 2026. The NDA filing with the FDA is expected to follow shortly after. Watch for that plenary presentation: it will likely be one of the most consequential moments in oncology this year.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.